 PRINCETON, N.J., July 01, 2021 GLOBE NEWSWIRE -- Oyster Point Pharma, Inc. Nasdaq: OYST, today announced preclinical data in non-human primates and in vitro models evaluating OC-01 varenicline nasal spray against SARS-CoV-2 and the alpha and beta variants, the viruses that cause COVID-19 disease. Administration of OC-01 varenicline nasal spray, a highly selective nicotinic acetylcholine receptor agonist, protected rhesus macaques against SARS-CoV-2 nasal infection. The results were published on the preprint server bioRxiv . 